Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCI-196 in CKD Stage V with Hyperphosphatemia
NCT00451295Phase 3Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- May 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in hyperphosphatemia comparing Placebo with MCI-196 (2 arms). Primary endpoint: Serum phosphorus change compared to placebo from baseline to week 12. Started May 2007; status: terminated.
02
Drugs
colestilan
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00451295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451295.